Kevin Kunzmann

Deepak L. Bhatt, MD, MPH, reviews the latest phase 2b trial data supporting the fast-acting monoclonal antibody infusion for bleeding risk reversal.

VOYAGER PAD subgroup analyses showed the anticoagulant reduced likelihood of hospitalization without increasing bleeding risk in patients with CKD.

Study author Brian Bergmark, MD, discusses what's next for the ANGTYL3 inhibitor, as well as promising developments in lipid-targeting therapies.

Larry Allen, MD, discusses some of ACC 2022's biggest contributions toward improving evidence-based care to patients with HF.

New phase 1 APOLLO data show the investigative single-dose siRNA infusion may address an inherent risk factor for severe cardiovascular events.

Larry Allen, MD, explains the significance of introducing SGLT-2 inhibitor recommendations to various stages of heart failure treatment and prevention guidelines.

A national survey assessment compared against the 6-item "ABCDs of ASCVD prevention" show the significant prevalence of obesity.

Investigators believe the novel monoclonal antibody may be a suitable agent in patients with major bleeding risk or those undergoing surgery.

New late-breaking ACC 2022 data support the use of antihypertensive therapy to reduce risk of events including preeclampsia and neonatal death among at-risk expecting mothers.

An investigator discusses new ACC 2022 data showing valvular heart disease is disparately impacting older patients, as well as females, with previously unanticipated manifestations.

Guideline writing committee co-chair Biykem Bozkurt, MD, PhD, discusses the utility of the drug class in HF prevention and risk reduction.

A new AAD study shows board-certified experts produce only one-fourth of the most popular TikTok posts on subjects in their field.

With the newest indication, the GLP-1 agonist is now available in 3 different doses for diabetic adults.

An assessment of long-term VOYAGER 1 and 2 trial data show the IL-23 biologic provides significant benefit toward skin clearance, regardless of baseline characteristics.

A pair of novel topical drugs hit high phase 3 marks at AAD 2022. One expert explains how they both may reach ground-breaking indications.

New AAD 2022 data support the novel gel therapy as the potentially first treatment for the viral-borne skin condition.

Amy S. Paller, MD, concludes her AAD 2022 interview with a look into the future of pediatric systemic therapy—and a call to assure due diligence in tracking patient progression among her peers.

Dedee F. Murrell, MD, details the EASE trial findings presented at AAD 2022, and what the benefit of the novel topical gel may mean for patients with EB.

A new AAD 2022 study shows disparities in patch testing for allergens—and how certain fragrances, metals and preservations discriminately affect rates of contact dermatitis.

The agent may become approved this year for children aged 6 months to 5 years old. Amy S. Paller, MD, discusses what impact it could bring.

New AAD 2022 data show the novel gene therapy from Krystal Biotech provided wound healing by 3 months in patients with dystrophic epidermolysis bullosa.

The Feinberg School of Medicine expert discusses the impact of dupilumab and other biologics on severely affected children and adolescnets.

An expert delves into the increased risk of conditions including psoriasis flares, lupus, and scleroderma following COVID-19.

International investigators observe differing levels of severe COVID-19 risk for patients with atopic dermatitis, dependent on their current therapy.

Data from the phase 3 TRuE-V clinical program show the topical JAK inhibitor provided substantial repigmentation to more than half of treated patients.

A Perelman School of Medicine assessment of biopsy rates support previous findings showing that dermatologists are less confident making psoriasis diagnoses in patients with darker skin color.

John E. Harris, MD, PhD, discusses the delayed decision date for the topical JAK inhibitor, and what more needs to be researched on the drug.

John E. Harris, MD, PhD, explains how JAK inhibitors and biologic therapy may advance the field from "Iron Age" era treatment strategy.

New AAD 2022 pooled analysis show the PDE-4 inhibitor topical therapy provides tolerable and effective improvement at 8 weeks.